Abstract
Leishmaniasis is a disease caused by flagellate protozoan Leishmania spp. and represents an emergent illness with high morbidity and mortality in the tropics and subtropics. Since the discovery of the first drugs for Leishmaniasis treatment (i.e., pentavalent antimonials), until the current days, the search for substances with antileishmanial activity, without toxic effects, and able to overcome the emergence of drug resistant strains still remains as the current goal. This article reports the development of new chemotherapies through the rational design of new drugs, the use of products derived from microorganisms and plants, and treatments related to immunity as new alternatives for the chemotherapy of leishmaniasis.
Similar content being viewed by others
References
Alexander J, Russel DG (1992) The interaction of Leishmania species macrophages. In: Baker JR, Muller R (eds) Advances in parasitology. vol. 131. Academic, New York, USA, pp 175–254
Arruda DC, Dalexandri FL, Katzin AM, Uliana SRB (2005) Antileishmanial activity of terpene nerolidol. Antimicrob Agents Chemother 49:1679–1687
Barral A, Pedral-Sampaio D, Grimaldi G Jr., Momen H, Mc Mahon-Pratt D, Ribeiro de Jesus A, Almeida R, Badaró R, Barral-Neto M, Carvalho EM, Johnson WD Jr (1991) Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 44:536–546
Berengener J, Gomez-Campdera F, Padilha B (1998) Visceral leishmaniasis (Kala-Azar) in transplant recipients: case report and review. Transplantation 65:1401–1404
Berman JD (1988) Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev Infect Dis 10:560–586
Bogdan C, Rollinghoff M, Solbato W (1990) Evasion strategies of leishmania parasite. Parasitol Today 6:183–187
Bogdan C, Gessner A, Solbach W, Rollinghoff M (1996) Invasion, control and persistence of leishmania parasites. Curr Opin Immunol 8:517–525
Bray PG, Barrett MP, Ward SA, Koning HP (2003) Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 19:232–239
Carvalho PB, Arribas MAG, Ferreira EI (2000) Leishmaniasis. What do we know about its chemotherapy? Braz J Pharm Sci 36:69–96
Chang KP (1990) Cell biology of leishmania. In: Wyler DW (ed) Modem parasite biology cellular, immunological and molecular aspects. Freeman, New York, pp 79–90
Corte-Real S, Santos CB, Meirelles MNL (1995) Differential expression of the plasma membrane Mg2+ ATPase and Ca2+ ATPase activity during adhesion and interiorization of Leishmania amazonensis in fibroblasts in vitro. J Submicrosc Cytol Pathol 27(3):359–366
Coura JR, Galvão-Castro B, Grimaldi JG (1987) Disseminated American cutaneous leishmaniasis in a patient with AIDS. Mem Inst Osw Cruz 82:581–582
Croft Sl, Seifert K, Yardley V (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res 123(3):399–410
Deane LM, Grimaldi G (1985) Leishmaniasis in Brazil. In: Chang KP, Bray RS (eds) Leishmaniasis. Elsevier, Amsterdam, pp 247–281
Delorenzi JC, Attias M, Gattass C, Andrade M, Rezende C, Pinto AC, Henriques AT, Bou-Habib DC, Saraiva EM (2001) Antileishmanial activity of na índole alkaloid from Peschiera australis. Antimicrob Agents Chemother 45(5):1349–1354
Desjeux P, Alvar J (2003) Leishmania/HIV. Co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97(suppp.1):3–15
Dey T, Anam K, Afrin F, Ali N (2000) Antileishmanial activities of stearylamina-bearing liposomes. Antimicrob Agents Chemother 44(6):1739–1742
Escobar P, Yardley V, Croft SL (2001) Activities of hexadecylphosphocholine (miltefosine), ambisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45(6):1872–1875
Golenser J, Frankenburg S, Ehrenfreund T, Domb AJ (1999) Efficacious treatment of experimental leishmaniasis with amphotericin b-arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 43(9):2209–2214
Gontijo B, Carvalho MLR (2003) Leishmaniose Tegumentar Americana. Revista de Sociedade Brasileira de Medicina Tropical 36(1):71–80
Gontijo CMF, Melo MN (2004) Leishmaniose Visceral no Brasil: Quadro Atual, Desafios e Perspectivas. Rev Bras Epidemiol 7(3):338–349
Green SJ, Meltzer MS Jr, Hibbs JB, Nacy CA (1990) Activated macrophages destroy intracellular Leishmania major amastigotes by an l-arginine-dependent killing mechanism. J Immunol 144:278–283
Grimaldi G Jr., Mc-Mahon-Pratt D, Sun T (1991) Leishmaniasis and its etiologic agents in the New World: an overview. Prog Clin Parasitol 2:73–118
Grimaldi G Jr., Corte-Real S, Pinho RT (1983) Interactions between Leishmania mexicana mexicana promastigotes and amastigotes and murine peritoneal macrophages in vitro. Mem Inst Osw Cruz 78:136–146
Hespanhol RC, Soeiro MNC, Corte-Real S (2005) The expression of mannose-receptor in skin fibroblast and their involvement in Leishmania (L.) amazonensis invasion. J Histochem Cytochem 53(1):35–44
Kar S, Kar K, Bhattacharya PK, Ghosh DK (1993) Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy. Antimicrob Agents Chemother 37(11):2459–2465
Kayser O, Kiderlen AF, Bertels S, Siems K (2001) Antileishmanial activities of aphidicolin and its semisynthetic derivatives. Antimicrob Agents Chemother 45(1):288–292
Kuhlencord A, Maniera T, Eibl H, Unger C (1992) Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36(8):1630–1634
Larabi M, Yardley V, Loiseau PM, Appel M, Legrand P, Gulik A, Bories C, Croft SL, Barratt G (2003) Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 47(12):3774–3779
Liew FY, O’Donnell CA (1993) Immunology of leishmaniasis. Adv Parasitol 32:161–259
Lima LM, Barreiro EJ (2005) Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med chem 12(1):23–49
Liñares GE, Ravaschino EL, Rodriguez JB (2006) Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 13:335–360
Ma G, Khan SI, Jacob MR, Tekwani BL, Li Z, Pasco DS, Walker LA, Khan IA (2004) Antimicrobial and antileishmanial activities of hipocrellins A and B. Antimicrob Agents Chemother 8(11):4450–4452
Mai A, Cerbara I, Valente S, Massa S, Walker LA, Tekwani BL (2004) Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides, a new class of histone deacetylas inhibitors. Antimicrob Agents Chemother 48(4):1435–1436
Mcgregor A (1998) WHO warns of epidemic Leishmania? Lancet 351:575–575
Molina R, Gradoni L, Alvar J (2003) HIV and the transmission of Leishmania. Ann Trop Med Parasitol 97(Suppl. 1):29–45
Morales P, Torres JJ, Salavert M, Peman J, Lacruz J, Sole A (2003) Visceral leishmaniasis in lung transplantation. Transplant Proc 35:2001–2003
Mukhopadhyay S, Bhattacharyya S, Majhi R, De T, Naskar K, Majumdar S, Roy S (2000) Use of attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. Clin Diagn Lab Immunol 7(2):233–240
Murray HW, Brooks EB, Devecchio JL, Heinzel FP (2003) Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother 47(8):2513–2517
Oliveira CC, Lacerda HG, Martins DR, Barbosa JD, Monteiro GR, Queiroz JW, Sousa JM, Ximenesf MF, Jerônimo SM (2004) Changing epidemiology of American cutaneous leishmaniasis (ACL) in Brazil: a disease of the urban–rural interface. Acta Trop 90(2):155–162
Olliaro PL, Bryceson ADM (1993) Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9:323–328
Pal S, Ravindran R, Ali N (2004) Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c mice. Antimicrob Agents Chemother 48(9):3591–3593
Raht S, Trivellin A, Imbrunito TR, Tomazela DM, Jesus MN, Marzal P, Junior HFA (2003) Tempone, A.G. Antimoniais Empregados no Tratamento da Leishmaniose: Estado de Arte. Quim Nova 26:550–557
Ramos H, Milhaud J, Cohen BE, Bolard J (1990) Enhanced action of anphotericin B on Leishmania mexicana resulting from heat transformation. Antimicrob Agents Chemother 34(8):1584–1589
Ritting MG, Bogdan C (2000) Leishmania host–cell interaction: complexities and alternative views. Parasitol Today 16:292–297
Roberts W, McMurray W, Rainey P (1998) Characterization of the antimonial antileishmanial agent meglumine antimonate (Glucantime). Antimicrob Agents Chemother 42(5):1076–1082
Rosa MSS, Mendonça-Filho RR, Bizzo HR, Rodrigues IA, Soares RM, Padrón TS, Alviano CS, Lopes AHCS (2003) Antileishmanial activity of a linalool-rich essential oil from Cróton cajucara. Antimicrob Agents Chemother 47(6):1895–1901
Sereno D, Alegre AM, Silvestre R, Vergnes B, Ouaissi A (2005) In vitro antileishmanial activity of nicotinamide. Antimicrob Agents Chemother 49(2):808–812
Shapiro TA, Were JB, Danso K, Nelson DJ, Desjardins RE, Pamplin CL (1991) Pharmacokinetics and metabolism of allopurinol riboside. Clin Pharmacol Ther 49(5):506–514
Silva ES, Pacheco RS, Gontijo CM, Carvalho IR, Brazil RP (2002) Visceral leishmaniasis caused by Leishmania (viannia) braziliensis in a patient infected with human immunodeficiency virus. Rev Inst Med Trop São Paulo 44:145–149
Singh S, Sivakumar R (2004) Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 10(6):307–315
Soong L, Duboise SM, Kima P, Mcmahon-Pratt D (1995) Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infection and Imunnity 63(9):3559–3566
Tempone AG, Silva ACMP, Brandt CA, Martinez FS, Borborema SET, Silveira MAB, Andrade HF Jr (2005) Synthesis and antileishmanial activities of novel 3-substituted quinolones. Antimicrob Agents Chemother 49(3):1076–1080
Tiuman TS, Nakamura TU, Cortez DAG, Filho BPD, Diaz JAM, Souza W, Nakamura CV (2005) Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 49(1):176–182
Weniger B, Robledo S, Arango GJ, Deharo E, Aragon R, Munoz V, Callapa J, Lobstein A, Anton R (2001) Antiprotozoal activities of Colombian plants. J Ethnopharmacol 78(2–3):193–200
WHO (2001) Tropical disease research: progress 1999–2000. World Health Organization, Geneva
WHO (1990) Tropical disease research progress. AIDS, leishmaniasis dangers of clash highlighted. TDR News. 36:1–11. World Health Organization
WHO (1991) Tropical disease research progress. Antimonials large-scale failure in Leishmaniasis “alarming”. TDR News. 34:17. World Health Organization
Yardley V, Khan AA, Martin MB, Slifer TR, Araujo FG, Moreno SNJ, Docampo R, Croft SL, Oldfield E (2002) In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplama gondii. Antimicrob Agents Chemother 46(3):929–931
Acknowledgment
The authors thank UFF, FIOCRUZ, CNPq, and FAPERJ for financial support and fellowships.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Santos, D.O., Coutinho, C.E.R., Madeira, M.F. et al. Leishmaniasis treatment—a challenge that remains: a review. Parasitol Res 103, 1–10 (2008). https://doi.org/10.1007/s00436-008-0943-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-008-0943-2